All In Biotech

Drug Trial Radar · NCT01716975

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Last checked: Nov 20, 2026Latest source record: May 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 767 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

767

Actual

Start

Oct 2012

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
FORUM Pharmaceuticals IncIndustry
Sponsor type
Industry
Collaborators
Syneos Health; NeuroCog Trials, Inc.
First posted
Oct 30, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

Conditions

  • Schizophrenia
  • Impaired Cognition

Interventions

  • EVP-6124Drug

    Arms 1, 2

  • PlaceboDrug

    Arm 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182Time frame: Baseline to Day 182 or Early Termination
  2. Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182Time frame: Baseline to Day 182 or Early Termination
  3. Safety and Tolerability of EVP-6124 or Placebo in Subjects with SchizophreniaTime frame: Screening (Day -42 to Day -15) to Day 182 or Early Terminiation

Locations

106 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenixville, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Cerritos, California

  • Site not named

    Chino, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Garden Grove, California

  • Site not named

    Glendale, California

  • Site not named

    Norwalk, California

  • Site not named

    Oakland, California

  • Site not named

    Oakland Park, California

  • Site not named

    Oceanside, California

  • Site not named

    Riverside, California

  • Site not named

    San Diego, California

  • Site not named

    San Gabriel, California

  • Site not named

    Santa Ana, California

  • Site not named

    Sherman Oaks, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Bradenton, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Springs, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Marietta, Georgia

  • Site not named

    Smyrna, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Oak Brook, Illinois

  • Site not named

    Oak Park, Illinois

  • Site not named

    Wichita, Kansas

  • Site not named

    Lake Charles, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Rockville, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Saint Charles, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Princeton, New Jersey

  • Site not named

    Jamaica, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Charlotte, North Carolina

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.